Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, ...

In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated ...

This webinar celebrating Global Biosimilars Week was hosted by The Center for Biosimilars® in partnership with the International Generics and Biosimilars Association. This webinar celebrating Global ...

Number 5: In 2 randomized controlled trials of maintenance therapy for inflammatory bowel disease (IBD), the subcutaneous formulation of the infliximab biosimilar CT-P13 demonstrated superiority to ...